Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sanofi-Aventis S.A. (SNY)

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,836,016
  • Shares Outstanding, K 2,517,944
  • Annual Sales, $ 42,687 M
  • Annual Income, $ 14,066 M
  • 60-Month Beta 0.57
  • Price/Sales 3.08
  • Price/Cash Flow 10.01
  • Price/Book 1.75
Trade SNY with:

Options Overview

Details
  • Implied Volatility 25.33%
  • Historical Volatility 15.21%
  • IV Percentile 35%
  • IV Rank 19.56%
  • IV High 47.72% on 04/20/20
  • IV Low 19.88% on 03/15/21
  • Put/Call Vol Ratio 7.00
  • Today's Volume 8
  • Volume Avg (30-Day) 410
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 3,559
  • Open Int (30-Day) 8,331

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.87
  • Number of Estimates 4
  • High Estimate 0.96
  • Low Estimate 0.79
  • Prior Year 0.90
  • Growth Rate Est. (year over year) -3.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.24 +4.10%
on 03/15/21
50.88 -1.30%
on 04/09/21
+2.21 (+4.60%)
since 03/12/21
3-Month
45.17 +11.18%
on 03/03/21
50.92 -1.37%
on 01/19/21
+2.18 (+4.54%)
since 01/13/21
52-Week
43.17 +16.33%
on 04/16/20
55.00 -8.69%
on 07/16/20
+5.84 (+13.16%)
since 04/13/20

Most Recent Stories

More News
Sanofi (SNY) Acquires Tidal to Aid mRNA-Based Research Platform

Sanofi's (SNY) acquisition of Tidal Therapeutics for $160 million is set to aid innovative mRNA-based research platform with applications in oncology, immunology and other diseases.

SNY : 50.31 (+0.12%)
ZTS : 163.40 (+0.55%)
RGEN : 210.13 (+1.50%)
ABBV : 107.20 (-0.97%)
Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines

, /PRNewswire/ -- In an , Sanofi Chief Executive Officer today outlined several key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy....

SAN : 3.44 (-0.86%)
SNY : 50.31 (+0.12%)
3 Large-Cap Stocks Trading at a Discount

With high hopes for a fast-paced recovery of the U.S. economy, market sentiment is upbeat. However, volatility and inflationary headwinds cannot be ruled out in the near term given the resurgence in COVID-19...

INTC : 64.58 (-1.27%)
SNY : 50.31 (+0.12%)
GSK : 35.89 (-0.47%)
Sanofi (SNY) Gets FDA Approval for Sarclisa Label Expansion

Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.

SNY : 50.31 (+0.12%)
BMY : 63.11 (+0.67%)
AMGN : 247.34 (-0.64%)
TBIO : 17.13 (+0.06%)
FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma

, /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with...

SAN : 3.44 (-0.86%)
SNY : 50.31 (+0.12%)
Novartis (NVS) Gets EC Nod For Kesimpta in Relapsing Forms of MS

The European Commission approves Novartis' (NVS) Kesimpta for the treatment of adult patients with relapsing forms of multiple sclerosis.

BIIB : 263.00 (+0.08%)
SNY : 50.31 (+0.12%)
GSK : 35.89 (-0.47%)
NVS : 86.36 (-1.12%)
4 Undervalued Pharmaceutical Stocks That Pay Dividends

The pharmaceutical industry has a reputation for resilience. Many pharma players that garnered noteworthy momentum amid the COVID-19 pandemic are holding strong even as the pandemic is on a decline. That’s...

PFE : 36.96 (-0.03%)
SNY : 50.31 (+0.12%)
BAYRY : 15.8200 (+0.06%)
ALPMY : 15.1400 (+1.54%)
J&J's (JNJ) Multiple Sclerosis Drug Ponesimod Gets FDA Nod

J&J's (JNJ) ponesimod demonstrated superior clinical efficacy in reducing annual relapses compared to Sanofi's Aubagio in clinical studies.

JNJ : 157.93 (-2.30%)
SNY : 50.31 (+0.12%)
NVS : 86.36 (-1.12%)
BMY : 63.11 (+0.67%)
Top Analyst Reports for Novo Nordisk, NextEra & 3M Company

Top Analyst Reports for Novo Nordisk, NextEra & 3M Company

USB : 57.01 (-1.16%)
SNY : 50.31 (+0.12%)
NVO : 70.44 (+1.41%)
NEE : 78.77 (+1.46%)
MMM : 196.16 (-0.84%)
GM : 58.17 (-2.50%)
Translate (TBIO) Down on Unsatisfactory CF Drug Study Results

Translate Bio (TBIO) announces data from second interim analysis of phase I/II study evaluating MRT5005 in patients with cystic fibrosis. The candidate fails to improve lung function in patients.

SNY : 50.31 (+0.12%)
ZTS : 163.40 (+0.55%)
TBIO : 17.13 (+0.06%)
CTLT : 107.31 (-1.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

3rd Resistance Point 50.95
2nd Resistance Point 50.80
1st Resistance Point 50.53
Last Price 50.31
1st Support Level 50.11
2nd Support Level 49.96
3rd Support Level 49.69

See More

52-Week High 55.00
Fibonacci 61.8% 50.48
Last Price 50.31
Fibonacci 50% 49.08
Fibonacci 38.2% 47.69
52-Week Low 43.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar